AbbVie (ABBV) Cost of Revenue (2012 - 2026)

AbbVie has disclosed Cost of Revenue across 15 years of filings, most recently posting $4.2 billion for Q1 2026.

• In Q1 2026, Cost of Revenue rose 5.4% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $18.4 billion (up 9.56% YoY), while the FY2025 annual figure was $18.2 billion, up 7.69% from the prior year.
• Cost of Revenue slipped to $4.2 billion in Q1 2026, from $4.6 billion in the prior quarter.
• Over the last five years, Cost of Revenue for ABBV reached as high as $6.5 billion in Q3 2023 and fell as low as $4.0 billion in Q1 2023.
• The 5-year median for Cost of Revenue is $4.2 billion (2026), against an average of $4.5 billion.
• Annual changes were most pronounced in 2023 — Cost of Revenue surged 36.79% — and 2024, when it tumbled 35.05%.
• A 5-year view of Cost of Revenue shows it stood at $4.2 billion in 2022, then surged by 36.79% to $5.7 billion in 2023, then fell by 22.93% to $4.4 billion in 2024, then grew by 3.55% to $4.6 billion in 2025, then fell by 7.34% to $4.2 billion in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4.2 billion, $4.6 billion, and $5.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.